card trial: cabazitaxel after ar-targeted therapy in mcspc
Published 4 years ago • 122 plays • Length 4:50Download video MP4
Download video MP3
Similar videos
-
1:22
cabazitaxel improves rpfs in patients with mcrpc
-
0:34
discussing the safety profile of cabazitaxel in mcrpc
-
4:34
card: cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
-
3:13
treatment options in metastatic prostate cancer
-
1:30
cabazitaxel impacts sequencing strategies in prostate cancer
-
2:01
managing aes in metastatic cspc: tropic and card trials
-
1:59
fred saad, md, shares impressions of the card study investigating cabazitaxel in nmcrpc patients
-
2:32
dr. sweeney on the optimal use of cabazitaxel
-
1:33
dr. oh discusses the utility of cabazitaxel
-
1:32
anis hamid, md, on impressions of the card study investigating the role of cabazitaxel in mcrpc
-
3:16
counseling patients with mcrpc
-
1:37
cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer
-
1:17
dr kyriakopoulos on adding cabazitaxel to abiraterone/prednisone in patients with mcrpc
-
5:56
card trial in metastatic crpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
2:04
a phase ii trial investigating neoadjuvant abiraterone and cabazitaxel in high-risk prostate cancer
-
0:33
expert discusses toxicity results in card study
-
3:59
researcher comment: cabazitaxel a new third-line option in mcrpc | ronald de wit
-
0:58
andrew armstrong, md, on impressions of the card study investigating cabazitaxel in mcrpc patients